TY - JOUR
T1 - Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation
T2 - A retrospective multicenter study
AU - COVID-19 ECMO Working Group
AU - Saeed, Omar
AU - Tatooles, Antone J.
AU - Farooq, Muhammad
AU - Schwartz, Gary
AU - Pham, Duc T.
AU - Mustafa, Asif K.
AU - D'Alessandro, David
AU - Abrol, Sunil
AU - Jorde, Ulrich P.
AU - Gregoric, Igor D.
AU - Radovancevic, Rajko
AU - Lima, Brian
AU - Bryner, Benjamin S.
AU - Ravichandran, Ashwin
AU - Salerno, Christopher T.
AU - Spencer, Philip
AU - Friedmann, Patricia
AU - Silvestry, Scott
AU - Goldstein, Daniel J.
AU - Alvarez, Chikezie
AU - DeAnda, Abe
AU - Gluck, Jason
AU - Jermyn, Rita
AU - Kuntzman, Matthew
AU - McKellar, Stephen
AU - Parides, Michael K.
AU - Saunders, Paul
N1 - Publisher Copyright:
© 2021 The American Association for Thoracic Surgery
PY - 2022/6
Y1 - 2022/6
N2 - Objective: To determine characteristics, outcomes, and clinical factors associated with death in patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) support. Methods: A multicenter, retrospective cohort study was conducted. The cohort consisted of adult patients (18 years of age and older) requiring ECMO in the period from March 1, 2020, to September 30, 2020. The primary outcome was in-hospital mortality after ECMO initiation assessed with a time to event analysis at 90 days. Multivariable Cox proportional regression was used to determine factors associated with in-hospital mortality. Results: Overall, 292 patients from 17 centers comprised the study cohort. Patients were 49 (interquartile range, 39-57) years old and 81 (28%) were female. At the end of the follow-up period, 19 (6%) patients were still receiving ECMO, 25 (9%) were discontinued from ECMO but remained hospitalized, 135 (46%) were discharged or transferred alive, and 113 (39%) died during the hospitalization. The cumulative in-hospital mortality at 90 days was 42% (95% confidence interval [CI], 36%-47%). Factors associated with in-hospital mortality were age (adjusted hazard ratio [aHR], 1.31; 95% CI, 1.06-1.61 per 10 years), renal dysfunction measured according to serum creatinine level (aHR, 1.21; 95% CI, 1.01-1.45), and cardiopulmonary resuscitation before ECMO placement (aHR, 1.87; 95% CI, 1.01-3.46). Conclusions: In patients with severe COVID-19 necessitating ECMO support, in-hospital mortality occurred in fewer than half of the cases. ECMO might serve as a viable modality for terminally ill patients with refractory COVID-19.
AB - Objective: To determine characteristics, outcomes, and clinical factors associated with death in patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) support. Methods: A multicenter, retrospective cohort study was conducted. The cohort consisted of adult patients (18 years of age and older) requiring ECMO in the period from March 1, 2020, to September 30, 2020. The primary outcome was in-hospital mortality after ECMO initiation assessed with a time to event analysis at 90 days. Multivariable Cox proportional regression was used to determine factors associated with in-hospital mortality. Results: Overall, 292 patients from 17 centers comprised the study cohort. Patients were 49 (interquartile range, 39-57) years old and 81 (28%) were female. At the end of the follow-up period, 19 (6%) patients were still receiving ECMO, 25 (9%) were discontinued from ECMO but remained hospitalized, 135 (46%) were discharged or transferred alive, and 113 (39%) died during the hospitalization. The cumulative in-hospital mortality at 90 days was 42% (95% confidence interval [CI], 36%-47%). Factors associated with in-hospital mortality were age (adjusted hazard ratio [aHR], 1.31; 95% CI, 1.06-1.61 per 10 years), renal dysfunction measured according to serum creatinine level (aHR, 1.21; 95% CI, 1.01-1.45), and cardiopulmonary resuscitation before ECMO placement (aHR, 1.87; 95% CI, 1.01-3.46). Conclusions: In patients with severe COVID-19 necessitating ECMO support, in-hospital mortality occurred in fewer than half of the cases. ECMO might serve as a viable modality for terminally ill patients with refractory COVID-19.
KW - ARDS
KW - COVID-19
KW - ECMO
KW - mortality
UR - http://www.scopus.com/inward/record.url?scp=85107350716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107350716&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2021.04.089
DO - 10.1016/j.jtcvs.2021.04.089
M3 - Article
C2 - 34112505
AN - SCOPUS:85107350716
SN - 0022-5223
VL - 163
SP - 2107-2116.e6
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 6
ER -